Accordingly, an adiponectin receptor (adipoR1/adipoR2) agonist “AdipoRon”, in clinical tests for Type 2 diabetes, is apparently effective in hepatic AMPK activation and counteraction of insulin resistance24, 68. This evidence concerns the gene ADIPOR2 and type 2 diabetes mellitus.